Sun Pharma receives USFDA approval for XiminoTM

Sun Pharmaceutical Industries has received approval from USFDA for its new drug used for acne treatment XiminoTM extended-release capsules in strengths of 45 mg, 90 mg and 135 mg. These are used for inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older. This approval strengthens the company’s branded dermatology portfolio in the US.

Company Profile : Sun Pharmaceutical Industries Ltd

Be the first to comment

Leave a Reply

Your email address will not be published.


*